分期伽玛刀联合贝伐珠单抗治疗散发性前庭神经鞘瘤的纵向肿瘤反应动态
该回顾性研究纳入72例散发性前庭神经鞘瘤患者,比较分期伽玛刀联合贝伐珠单抗(49例)与单次伽玛刀 alone(23例)的纵向肿瘤反应。联合治疗组显示更早、更持续的肿瘤退缩,早期瘤体增大风险显著降低(14.3% vs 60.9%,HR 0.16,95%CI 0.06-0.40,P<0.001)。假性进展发生率数值上更低(4.1% vs 17.4%),但无统计学差异(P=0.078)。
要点
- 分期GKRS联合贝伐珠单抗较单次GKRS alone显著降低早期治疗后瘤体增大风险(14.3% vs 60.9%,HR 0.16,P<0.001)。
- 联合治疗组肿瘤退缩更早、更持续,治疗与时间交互作用P<0.001。
- 假性进展发生率数值上更低(4.1% vs 17.4%),但差异无统计学意义(P=0.078)。
核心结论
- 分期GKRS联合贝伐珠单抗与散发性VS更早、更持续的肿瘤退缩及更低的早期治疗后增大风险相关。
- 较大的基线肿瘤体积和囊性成分与更显著的肿瘤退缩相关。
- 假性进展在联合组数值上更少,但差异未达统计学显著。
研究设计与样本
- 回顾性队列研究,纳入72例散发性前庭神经鞘瘤患者。
- 49例接受分期GKRS联合贝伐珠单抗,23例接受单次GKRS alone。
- 纵向肿瘤体积变化采用多变量线性混合效应模型分析;早期体积增大采用Kaplan-Meier估计和Cox比例风险模型评估。
主要发现
- 联合治疗组与单次GKRS alone组的肿瘤反应轨迹显著不同(治疗-时间交互作用P<0.001)。
- 早期体积增大(>10%)在联合组与单次组的发生率分别为14.3%与60.9%(HR 0.16;95%CI 0.06-0.40;P<0.001)。
- 假性进展发生率在联合组与单次组分别为4.1%与17.4%,差异无统计学意义(P=0.078)。
- 囊性肿瘤成分与更显著的肿瘤退缩独立相关。
- 贝伐珠单抗相关不良事件轻微且可控。
临床怎么用
- 对于散发性前庭神经鞘瘤,分期GKRS联合贝伐珠单抗可能减少早期治疗后瘤体增大和假性进展的临床困扰。
- 基线肿瘤体积较大或含囊性成分的患者可能从联合治疗中获得更显著的肿瘤退缩。
- 贝伐珠单抗相关不良事件轻微可控,支持在该联合方案中监测和管理安全性。
局限性
- 回顾性研究设计,样本量有限(共72例,单次GKRS alone组仅23例)。
- 假性进展差异未达统计学显著,需更大样本验证。
- 联合治疗与单次治疗组的比较可能受选择偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clin Transl Radiat Oncol . 2026 Oct 14;62:101318. doi: 10.1016/j.ctro.2026.101318. eCollection 2027 Jan. ABSTRACT BACKGROUND: Vestibular schwannomas (VSs) are benign tumors of the eighth cranial nerve. Although Gamma Knife radiosurgery (GKRS) achieves durable tumor control, delayed regression and pseudoprogression remain clinical challenges. Staged GKRS combined with bevacizumab may alter post-radiosurgical tumor response patterns. AIM: To compare longitudinal tumor response, pseudoprogression, and clinical outcomes between staged GKRS combined with bevacizumab and single-session GKRS alone in sporadic VSs. METHODS: We retrospectively reviewed 72 patients with sporadic VSs: 49 treated with staged GKRS plus bevacizumab and 23 with single-session GKRS alone. Longitudinal tumor volume changes were analyzed using multivariable linear mixed-effects models, while early volumetric enlargement was evaluated using Kaplan-Meier estimates and Cox proportional hazards models. RESULTS: Compared with GKRS alone, staged GKRS plus bevacizumab showed significantly different response trajectories (treatment-by-time interaction, P 10%) occurred in 14.3% versus 60.9% of patients (HR, 0.16; 95% CI, 0.06-0.40; P < 0.001). Pseudoprogression occurred in 4.1% versus 17.4% of patients, without statistical significance ( P = 0.078). Cystic tumor composition was independently associated with greater regression. BEV-related adverse events were mild and manageable. CONCLUSION: Staged GKRS combined with bevacizumab was associated with earlier, more sustained tumor regression and a lower risk of early post-treatment enlargement in sporadic VSs. Larger baseline tumor volume and cystic composition were associated with greater regression. Pseudoprogression was numerically less frequent, although the difference was not statistically significant. TRIAL REGISTRATION: ChiCTR2600131856 (Chinese Clinical Trial Registry). PMID: 42936495 | PMC: PMC13698073 | DOI: 10.1016/j.ctro.2026.101318
引用
- PubMed 顶刊 · 中枢神经:Longitudinal tumor response dynamics after staged gamma knife radiosurgery combined with bevacizumab in sporadic vestibular schwannoma
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。